For adults with depression that didn’t respond to other treatments, using a nasal spray called esketamine for six months seemed to help fewer people think about suicide — down from more than half to about one in seven — but how strongly they felt those thoughts didn’t clearly get better.
Claim Language
Language Strength
association
Uses association language (linked to, correlated with)
The claim uses 'is associated with' and 'showed only a non-significant trend toward improvement,' which indicate correlation rather than causation or certainty. These phrases avoid claiming direct cause or definitive effect, aligning with association-level language.
Context Details
Domain
medicine
Population
human
Subject
Adults with treatment-resistant depression
Action
is associated with
Target
a reduction in suicidal ideation prevalence from 52.4% at baseline to 14.3% at six months, with a non-significant trend toward improvement in intensity scores
Intervention Details
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Evidence from Studies
Supporting (1)
This study gave people with severe depression a nasal spray called esketamine for six months and found that fewer of them thought about suicide by the end, which matches what the claim says.